Insider · CIK 0001837524
Corrine Savill
Files at CGEM (Cullinan Therapeutics, Inc.). First filing -, latest -.
Corrine Savill files SEC Form 4 as officer at CGEM (Cullinan Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Corrine Savill has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 18, 2026 | CGEM Cullinan Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +175,000 | $0.00 | $0 | 175,000 | Feb 19, 2026 |
| Feb 19, 2025 | CGEM Cullinan Therapeutics, Inc. | AGrant or award Common Stock | +37,500 | $0.00 | $0 | 240,990 | Feb 21, 2025 |
| Feb 19, 2025 | CGEM Cullinan Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +75,000 | $0.00 | $0 | 75,000 | Feb 21, 2025 |
Questions about Corrine Savill
Answered from the filings on this page, as of the latest one.
Is Corrine Savill buying or selling?
Corrine Savill has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Corrine Savill's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Corrine Savill has 0.
Where does Corrine Savill file Form 4?
Corrine Savill has filed Form 4 at CGEM (Cullinan Therapeutics, Inc.) as Chief Business Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.